Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Weekly Ratings as of Dec 8, 2018

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Corporate Logo

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Ratings Coverage

In total 3 analysts cover Fresenius Medical Care (NYSE:FMS). “Buy” rating has 2, “Sell” are 0, while 1 are “Hold”. (NYSE:FMS) has 67% bullish analysts. 3 are the (NYSE:FMS)’s ratings reports on Dec 8, 2018 according to StockzIntelligence Inc. On Thursday, October 18 the rating was downgraded by DZ Bank to “Hold”. On Friday, October 26 the company was upgraded by UBS. On Tuesday, August 28 the firm earned “Buy” rating by HSBC. Listed here are Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) PTs and latest ratings.

26/10/2018 Broker: UBS Old Rating: Neutral New Rating: Buy Upgrade
18/10/2018 Broker: DZ Bank Old Rating: Buy New Rating: Hold Downgrade
28/08/2018 Broker: HSBC Old Rating: Hold New Rating: Buy Upgrade

FMS touched $35.67 during the last trading session after $3.56 change.Fresenius Medical Care AG & Co. KGaA has 749,471 shares volume, 208.65% up from normal. FMS is uptrending and has moved 4.38% since December 8, 2017. FMS underperformed by 11.24% the S&P 500.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services.The company has $21.85 billion market cap. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure.9.66 is the P/E ratio. The firm also develops, makes, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, and endovascular specialty, as well as hospitalist and intensivist, and medical cost management services.

For more Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) news published briefly go to: Seekingalpha.com, Seekingalpha.com, Nasdaq.com, Benzinga.com or Seekingalpha.com. The titles are as follows: “NxStage Medical down 6% – Seeking Alpha” published on November 30, 2018, “APC, NBL among premarket gainers – Seeking Alpha” on November 07, 2018, “Why Cara Therapeutics Is Up 50% in 2018 – Nasdaq” with a publish date: December 02, 2018, “25 Stocks Moving In Friday’s Pre-Market Session – Benzinga” and the last “Merger Arbitrage Opportunity In NxStage Medical – $30 Cash Offer From Fresenius – Seeking Alpha” with publication date: February 08, 2018.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.